Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on EquityReturn on Sales

Innate Pharma (IPHA) Assets Average (2018 - 2025)

Historic Assets Average for Innate Pharma (IPHA) over the last 6 years, with Q2 2025 value amounting to $631.3 million.

  • Innate Pharma's Assets Average fell 2559.96% to $631.3 million in Q2 2025 from the same period last year, while for Jun 2025 it was $631.3 million, marking a year-over-year decrease of 2559.96%. This contributed to the annual value of $154.9 million for FY2024, which is 2287.7% down from last year.
  • As of Q2 2025, Innate Pharma's Assets Average stood at $631.3 million, which was down 2559.96% from $733.8 million recorded in Q4 2024.
  • Over the past 5 years, Innate Pharma's Assets Average peaked at $334.3 billion during Q2 2021, and registered a low of $631.3 million during Q2 2025.
  • In the last 5 years, Innate Pharma's Assets Average had a median value of $1.1 billion in 2023 and averaged $93.5 billion.
  • In the last 5 years, Innate Pharma's Assets Average dropped by 6.89% in 2021 and then crashed by 9963.63% in 2022.
  • Innate Pharma's Assets Average (Quarter) stood at $334.1 billion in 2021, then plummeted by 99.64% to $1.2 billion in 2022, then decreased by 19.74% to $975.3 million in 2023, then decreased by 24.77% to $733.8 million in 2024, then dropped by 13.97% to $631.3 million in 2025.
  • Its Assets Average stands at $631.3 million for Q2 2025, versus $733.8 million for Q4 2024 and $848.5 million for Q2 2024.